SPONSOR
Peking University Cancer Hospital & Institute
Total Trials
5
Recruiting
5
Phases
Phase 2, Phase 1, Phase 2
Conditions studied: Non-Small Cell Lung CancerNon Small Cell Lung Cancer NSCLCLimited-stage Small Cell Lung Cancer (LS-SCLC)Esophageal Cancer (EsC)Digestive System Cancers
NCT05104788 Phase 2
Recruiting
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
NCT07087223 Phase 1, Phase 2
Recruiting
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
Non Small Cell Lung Cancer NSCLC
NCT06869239
Recruiting
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06869213 Phase 2
Recruiting
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
Esophageal Cancer (EsC)
NCT06099821 Phase 2
Recruiting
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Digestive System Cancers